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Individuals with mutation in the lysosomal enzyme glucocerebrosidase (GBA) gene are at significantly high risk of developing
Parkinson’s disease with cognitive deficit. We examined whether visual short-term memory impairments, long associated with
patients with Parkinson’s disease, are also present in GBA-positive individuals—both with and without Parkinson’s disease.
Precision of visual working memory was measured using a serial order task in which participants observed four bars, each of a
different colour and orientation, presented sequentially at screen centre. Afterwards, they were asked to adjust a coloured probe
bar’s orientation to match the orientation of the bar of the same colour in the sequence. An additional attentional ‘filtering’
condition tested patients’ ability to selectively encode one of the four bars while ignoring the others. A sensorimotor task using
the same stimuli controlled for perceptual and motor factors. There was a significant deficit in memory precision in GBA-positive
individuals—with or without Parkinson’s disease—as well as GBA-negative patients with Parkinson’s disease, compared to
healthy controls. Worst recall was observed in GBA-positive cases with Parkinson’s disease. Although all groups were impaired
in visual short-term memory, there was a double dissociation between sources of error associated with GBA mutation and
Parkinson’s disease. The deficit observed in GBA-positive individuals, regardless of whether they had Parkinson’s disease, was
explained by a systematic increase in interference from features of other items in memory: misbinding errors. In contrast,
impairments in patients with Parkinson’s disease, regardless of GBA status, was explained by increased random responses.
Individuals who were GBA-positive and also had Parkinson’s disease suffered from both types of error, demonstrating the worst
performance. These findings provide evidence for dissociable signature deficits within the domain of visual short-term memory
associated with GBA mutation and with Parkinson’s disease. Identification of the specific pattern of cognitive impairment in
GBA mutation versus Parkinson’s disease is potentially important as it might help to identify individuals at risk of developing
Parkinson’s disease.
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Introduction
One of the key priorities in Parkinson’s disease research is to
detect the disease at its earliest stage. Cognitive deficits, including
those in visual working memory or the storage component of
working memory, referred to as visual short-term memory
(VSTM), are an important feature of Parkinson’s disease, often
apparent at very early stages of the disease (Owen et al., 1992,
1993, 1997; Dujardin et al., 1999; Muslimovic et al., 2005;
Verbaan et al., 2007; Savica et al., 2010). Such impairments
potentially provide a means for early detection. However,
screening for deficits on a population-wide basis would be an
extremely challenging undertaking (Berg et al., 2012).
An alternative strategy is to target individuals who are at
particularly high risk of developing Parkinson’s disease due, for
example, to genetic factors. Recently mutation in the gene
encoding the lysosomal enzyme glucocerebrosidase (GBA) has
been identified as the highest genetic risk factor for developing
Parkinson’s disease (Clark et al., 2009; Neumann et al., 2009;
Sidransky et al., 2009). Mutations in this gene have classically
been associated with Gaucher’s disease, a condition that results
from homozygosity or compound heterozygosity for GBA
mutations (Pastores and Hughes, 1993). The odds ratio of
having a GBA mutation in Parkinson’s disease is 45 (Sidransky
et al., 2009), whereas the lifetime risk of developing Parkinson’s
disease has been found to be 21-fold greater in patients with
Gaucher’s disease compared to control subjects (Bultron et al.,
2010).
Individuals with GBA mutations are therefore a potentially
important group of people to screen for impairments that might
be associated with Parkinson’s disease. Here we focused on
cognitive deficits, which have long been associated with
established Parkinson’s disease (Bradley et al., 1989; Owen
et al., 1992, 1993, 1997; Owen, 2004), most prominently
impairments in working memory and attention (Cooper et al.,
1991; Owen et al., 1992; Dujardin et al., 1999; Muslimovic
et al., 2005).
It has now been established that cognitive impairments in
patients with Parkinson’s disease who are heterozygous carriers
of GBA mutations are more frequent and severe than in patients
with GBA-negative Parkinson’s disease, as indexed by the
Montreal Cognitive Assessment (Brockmann et al., 2011).
Furthermore, visual working memory performance is severely
impairment in cases with GBA-positive early-onset Parkinson’s
disease compared to patients with GBA-negative Parkinson’s
disease (Alcalay et al., 2012). Finally, GBA-positive individuals
with Parkinson’s disease are more likely to develop dementia
than those without (Winder-Rhodes et al., 2013). Together,
these findings suggest that GBA mutation is an important risk
factor for cognitive impairments in Parkinson’s disease.
But based on these results alone, one cannot conclude whether
such deficits are due to GBA pathology, manifestation of
Parkinson’s disease or a combination of these factors. Indeed
GBA-positive individuals without Parkinson’s disease have also
been shown to be impaired on the Montreal Cognitive
Assessment as well as a test of olfaction, a potential marker for
early neurodegeneration (McNeill et al., 2012). Clarification of this
issue and identification of the signature of cognitive impairment in
people with GBA mutation versus those with Parkinson’s disease is
potentially important as it might help to identify individuals at risk
of developing Parkinson’s disease.
Given that visual working memory/short-term memory deficits
have been reported in early Parkinson’s disease (Owen et al.,
1992, 1993, 1997; Muslimovic et al., 2005) and in patients with
GBA-positive Parkinson’s disease (Alcalay et al., 2012), we
focused on VSTM in GBA-positive individuals with and without
Parkinson’s disease, as well as sporadic (GBA-negative) cases of
Parkinson’s disease to investigate whether the pattern of VSTM
deficit associated with GBA and Parkinson’s disease pathology is
dissociable. We used a relatively new experimental method of
measuring VSTM that, unlike conventional clinical measures of
memory ‘span’, examines the resolution with which items are
maintained and later recalled. In tasks similar to the one we
used, participants are asked to remember visual features and
reproduce the exact qualities of those features when, after a
retention period, they are probed to recall an item (Bays et al.,
2009; Gorgoraptis et al., 2011; Zokaei et al., 2011; Pertzov et al.,
2013).
Importantly, such VSTM precision tasks also provide a means to
dissect out sources of error contributing to the pattern of
performance. In paradigms similar to the one we used, error can
potentially arise from three sources. First, it can be due to
variability in memory for the probed item; how well it is stored.
Second, participants may make random errors because, on some
trials, they are simply guessing, e.g. they failed to encode the
probed item or to retrieve it. Finally, and importantly, error can
arise from misreporting features of non-probed items that were
presented in the memory array, instead of reporting the features
that belonged to the probed item. In other words, an observer’s
response might be systematically biased by other objects that were
encoded into VSTM. By applying a recent analytical technique
(Bays et al., 2009) we were able to estimate the proportion of
responses arising from each of these sources of error and to find
signature VSTM deficits associated with GBA mutation and
Parkinson’s disease.
Materials and methods
Patients and age-matched control
subjects
Twenty GBA-positive individuals without Parkinson’s disease were
tested: nine with type 1 Gaucher’s disease and 11 heterozygote
GBA mutation carriers (without Gaucher’s disease). The patients with
type 1 Gaucher’s disease were not receiving substrate reduction
therapy. There was no difference in all our measures (i.e. overall
VSTM performance, proportion of target, non-target and random
responses) between patients with Gaucher’s disease and individuals
with heterozygote GBA mutation and hence these two groups, for
the rest of the analysis, have been collapsed (n = 20). GBA-positive
individuals were recruited from the Lysosomal Storage Disorder Unit at
the Royal Free Hospital, London and UK Gaucher Disease Association.
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All GBA-positive individuals scored zero for all subscales of the Unified
Parkinson’s Disease Rating Scale (UPDRS). All GBA-positive individuals
were aware of their GBA status.
Eighteen GBA-positive patients with Parkinson’s disease (daily
levodopa equivalent dose: 628 mg) (Tomlinson et al., 2010) and 15
GBA-negative patients with Parkinson’s disease (daily levodopa
equivalent dose: 647 mg) were also tested. GBA-positive and
GBA-negative cases with Parkinson’s disease were recruited from
Oxford Parkinson’s Disease Centre (OPDC) cohort study (PD
discovery) and were aware of their GBA status or underwent genetic
testing by the Lysosomal Storage Disorder Unit at the Royal Free
Hospital London after being diagnosed with Parkinson’s disease in
the Department of Neurology, UCL and were later informed of their
GBA status. None of the patients with GBA-positive Parkinson’s
disease were related to one another or related to GBA-positive
cases. Patient demographics are presented in Table 1.
All patients scored 30/30 on the Mini-Mental State Examination
(Folstein et al., 1975) except three GBA-positive patients with
Parkinson’s disease who were excluded from the rest of the analysis
(information on UPDRS scores of patients with Parkinson’s disease,
both GBA-negative and positive are presented in Supplementary
Tables 1 and 2). For comparison 17 healthy control participants,
matched to patients for age and years of education, also participated
in this study (Table 1). Control participants had no neurological disease
or history of Gaucher’s disease in their family.
Some patients and healthy controls were also tested on verbal
working memory task (forwards and backwards digit span) with no
significant difference in performance between groups (Supplementary
Table 3). All participants had normal or corrected to normal vision and
colour vision and provided written informed consent to the procedure
of the experiment, approved by the local ethics committee.
Genetic testing
Patients with GBA-positive Parkinson’s disease were screened
for N370S and L444P mutations in the GBA gene by
extracting genomic DNA from blood samples using the
AutoPure LS

(QIAGEN). PCR reactions were carried out with
AmpliTaq Gold

DNA polymerase (Applied Biosystems). Primer se-
quences used for N370S were: 5’- GCCTTTGTCCTTACCCTC*G -3’
and 5’- GACAAAGTTACGCACCCAA-3’. A mismatch was engineered
into the forward primer in order to create a XhoI restriction
site in the PCR product from participants carrying the
N370S mutation. For the L444P mutation primers used were:
5’-GGAGGACCCAATTGGGTGCGT-3’ and 5’-ACGCTGTCTTCAGCC
CACTTC-3’. The resulting PCR products were digested with XhoI
(NEB) for N370S and NciI (NEB) for L444P and resolved by agarose
gel electrophoresis. Mutations were then confirmed by sequencing.
Briefly, DNA was treated with an ExoSAP reaction as follows:
1  SAP buffer, shrimp alkaline phosphatase (500U; SAP, Promega),
Exonuclease I (2U; NEB). Samples were incubated at 37C for 1 h and
then 80C for 20min. The sequencing reaction was performed accord-
ing to BigDye

Terminator v3.1 Cycle Sequencing protocol (Applied
Biosystems). Following a clean-up step, the sequencing read was
performed on a 3700 DNA Analyser (Applied Biosystems) sequencing
platform.
GBA mutation in non-Parkinson’s disease cases was confirmed by
sequencing exons 1 to 11 of the GBA gene using published protocol
(Neumann et al., 2009) with PCR designed for regions of the GBA
gene not found in pseudogene. After amplification by PCR the product
was run on 1% agarose gel with ethidium bromide and size-checked
to ensure intronic sequences using the Dye Terminator Sequencing Kit
(Applied Biosystems) on an ABI 3700xl genetic analyser. Of the 20
tested GBA-positive individuals, three had mutations other than the
two most common mutations N370S and L444P (RecNcil, V3494L and
W184R).
Experimental visual short-term memory
task
The task was adapted from that previously used by Gorgoraptis et al.
(2011). Stimuli were presented on a laptop monitor (32  19) at a
viewing distance of 52 cm. A schematic representation of the task is
shown in Fig. 1A. In each trial, a sequence of four coloured bars
(2  0.2) was presented at screen centre on a grey background.
Each bar was presented for 500ms followed by a 500ms blank interval
before the presentation of the next bar. The colours in each trial
were selected randomly—with no repetition within a trial—from five
easily distinguished colours (red, yellow, green, blue and purple).
Minimum angular separation between the orientation of bars within
the same sequence was 10; the orientation was chosen randomly
otherwise. Participants were asked to remember the orientation of
each bar.
At the end of each trial, a probe bar oriented randomly, in the same
colour as one of the bars in the sequence was presented. A circle
surrounding this probe made it easier to distinguish from bars in the
sequence. Participants were instructed to use a rotating dial (which
controlled the orientation of the probe bar) to match the orientation
of the probe with the same coloured bar they had seen in the
sequence. The black circle surrounding the probe item disappeared
upon rotating the dial. Participants clicked on the dial once they had
rotated the dial to their selected orientation. Stimuli presented in any
of the serial positions within the sequence were probed with equal
probability and participants did not know beforehand which item
would be tested.
Table 1 Demographic information on all patient groups and healthy controls
Age (years) Gender Years
of education
Mean (SD) Male/female Mean (SD)
GBA-positive non-Parkinson’s disease cases (n = 20) 61 (9) 11/9 15 (2)
GBA-negative Parkinson’s disease patients (n = 15) 63 (6) 9/6 13.5 (5)
GBA-positive Parkinson’s disease patients (n = 15) 60 (8) 7/8 14 (3)
Healthy controls (n = 17) 61.5 (10) 9/8 15 (3)
SD = standard deviation.
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Control tasks
It is possible that poor performance in our experimental VSTM task
might be due to factors other than the ability to maintain four items.
The following tasks, administered in random order across participants,
were used as controls to ensure that various issues were not a concern
for subsequent interpretation.
Pre-cueing condition
Stimuli were identical to those in the experimental VSTM task except
for the following. At the beginning of each block, a 100% valid cue
would inform participants to maintain the orientation of a bar
presented in a specific colour in the subsequent sequence of four
oriented bars. Participants were always probed on the cued item at
the end of the sequence. This task was employed to control for any
deficits in attentional filtering across groups.
One item working memory task
In each trial, participants were presented with a single oriented bar at
screen centre for 500ms. Following a blank variable delay, a probe bar
of the same colour appeared and participants were asked to adjust
the probe bar’s orientation to match the orientation of the target bar
(Fig. 1B). The maintenance period preceding the probe was randomly
chosen from one of the following delays: 500, 1500, 2500 and
3500ms. The duration of the retention periods matched the durations
from presentation of probed bars at different serial positions within
four-item sequences used in the experimental VSTM task. This task
was used to control for temporal decay of information in working
memory.
Sensorimotor control task
In each trial a coloured oriented bar was presented at screen centre.
Five hundred milliseconds after the presentation of the bar, a probe
bar of the same colour surrounded by a black circle appeared below
the target bar. Participants were asked to adjust the probe bar’s
orientation on screen to match the orientation of the target
which remained on screen until response (Fig. 1C). The orientation
of the target and the probe were independently randomized on
each trial.
For each of the experimental VSTM, pre-cueing and one-item VSTM
tasks GBA-positive individuals completed 100 trials, patients with
GBA-negative and positive Parkinson’s disease completed 50–200
trials (depending on their availability) and control participants
performed 200 trials. All GBA-positive individuals, patients with
Figure 1 (A) A sequence of four coloured oriented bars were presented sequentially. Any of the bars could be probed by colour of the
response stimuli and participants were asked to adjust the orientation of the response stimuli to the orientation of the bar with same
colour. (B) An example of the one-item working memory task. A rotating dial is used to orient the probe bar (surrounded by circle) to
match the orientation of the target bar presented following a delay. (C) An example sensorimotor task. A rotating dial is used to orient the
probe bar (surrounded by circle) to match the orientation of the target bar presented above the probe.
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GBA-negative and positive Parkinson’s disease and 10 aged-matched
controls completed 20 trials of the sensorimotor control task.
Analysis
We calculated recall precision as the reciprocal of the circular
standard deviation of response error (the difference in response
and target angle) (Philipp, 2009). Precision is a measure of
response variability, less variability corresponding to more precise
memory.
To identify mechanisms underlying VSTM impairment associated
with Parkinson’s disease and GBA mutation, we also fit a mixture
model that dissociates different sources of error in memory previously
introduced by Bays et al. (2009) (see also http://www.sobell.ion.ucl.a
c.uk/pbays/code/JV10/). The mixture model is described by the
following equation:
pð^Þ ¼ kð^  Þ þ 
1
m
Xm
i
k ^  ’i
 
þ 
1
2
ð1Þ
Several sources of error can contribute to impaired performance. Error
can arise due to increased variability in memory for orientation of the
probed item, captured by model parameter , where higher  corres-
ponds to lower variability in memory for the orientation (Fig. 2A).
Increase in random responses, i.e. guesses (Fig. 2B), captured by 
in the model. Successful performance also requires memory for correct
combination of orientation and colour. Therefore errors can also arise
as a result of incorrect conjunction of colour and orientation (mis-
binding errors). In such trials participants make an error centred on
the orientation of other (non-probed) items in memory (Fig. 2C).
In more concrete terms: if the probed item is red (as in Fig. 1A) but
the participants responds with the orientation of one of the other
coloured bars in the sequence, this would be classified as a misbinding
error.
The probability of responding to non-probed items is captured by
parameter b in the model, the probability of responding with the
probed orientation is given by . Maximum likelihood parameters of
, , b and  were obtained using the well-established expectation
maximization (Myung, 2003) procedure for each participant (full
details are given in Bays et al., 2009).
Results
Visual short-term memory impairments
in individuals with GBA mutation and
Parkinson’s disease
There was a main effect of both Parkinson’s disease and GBA
mutation on precision of recall [F(1,63) = 12.5, P = 0.001 and
F(1,63) = 7.6, P50.01, respectively; Fig. 3A]. Compared to
healthy participants, performance was significantly worse—less
precise—in patients with Parkinson’s disease, both GBA-negative
and GBA-positive carriers [t(30) = 2.9, P50.01 and t(30) = 4.99,
P50.001, respectively]. In addition, GBA-positive individuals
without Parkinson’s disease were significantly impaired compared
to controls [t(35) = 2.3, P5 0.05]. Importantly, patients with
GBA-positive Parkinson’s disease had significantly less precise
memory compared to cases with GBA-negative Parkinson’s
disease [t(28) = 2.1, P5 0.05] as well as GBA-positive individuals
without Parkinson’s disease [t(33) = 2.04, P50.05].
Sources of error in visual short-term
memory impairments associated with
GBA mutation and Parkinson’s disease
Although all three groups of interest were significantly impaired in
the VSTM task compared to healthy participants, the overall
performance does not inform us about the sources of error
associated with Parkinson’s disease and GBA mutation. Are
these the same or can they be distinguished?
Figure 2 Three sources of error in memory used for mixture modelling. This figure is a schematic presentation of the three possible
sources of error that can occur in working memory. (A) A Von Mises (circular Gaussian) distribution with concentration parameter ,
centred on the probed value, capturing variability in memory for target, with the area under the distribution (shaded) being proportional to
the probability of responding to the probe. (B) A uniform distribution of error corresponding to random error, with the area under this
distribution corresponding to the proportion of random responses. (C) Von Mises distribution with concentration parameter , centred on
one of the non-probe value, resulting from errors in identifying which orientation belonged with the probed colour (binding failures). The
area under the distribution corresponds to the proportion of non-probed responses.
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Examination of the distribution of error in relation to the
orientation of the probed item revealed a main effect of group
at the peak of the distribution [F(3,63) = 4.95, P50.005]. At the
peak of the distribution, there was a significant decrease in
proportion of responses in GBA-positive individuals, either with
[t(30) = 4.06, P5 0.001] or without Parkinson’s disease
[t(35) = 2.99, P = 0.005], compared to healthy controls.
The proportion of responses falling close to the orientation of
the probed item was lowest in patients with GBA-positive
Parkinson’s disease (Fig. 3B).
A plot of the distribution of error in relation to the non-probed
orientations (i.e. the orientations of other items held in VSTM that
were not probed) demonstrated a significant increase around
non-probed orientations at the peak of the distribution in both
GBA-positive Parkinson’s disease [t(30) = 3.12, P50.005] and
GBA-positive cases without Parkinson’s disease [t(35) = 5.65,
P5 0.001 compared to healthy controls (Fig. 3C). The peak of
non-probed responses was significantly higher in patients with
GBA-positive Parkinson’s disease compared to cases with
GBA-negative (sporadic) Parkinson’s disease [t(28) = 2.15,
P5 0.05]. Thus, regardless of whether they had Parkinson’s
disease, individuals who were GBA-positive demonstrated
increased error due to responding to non-probed items. In other
words, these patients erroneously misbound the colour of the
probed orientation with non-target orientations (i.e. orientations
of other items in the sequence).
To quantify the possible sources of error, we next applied
the mixture model of response error described above to our
data (Bays et al., 2009) (see above). Maximum likelihood
estimates of the probability of responding with the probed
orientation (), proportion of responding to non-probed orienta-
tions (b), and proportion of random responses or guessing ()
were estimated together with the variability in recall of target
orientation (). After model fitting, any individual with outlier
parameter values (defined as values 2.5 standard deviations from
the mean of each parameter) were excluded. One healthy partici-
pant, one individual with GBA mutation, one Parkinson’s disease
GBA-negative and two Parkinson’s disease GBA-positive patients
were excluded.
In line with the distribution of error around the probed
item (Fig. 3B), there was a main effect of both Parkinson’s
disease and GBA mutation on , the probability of responses to
this orientation [F(1,59) = 7.4, P50.01 and F(1,59) = 8.4,
P = 0.005, respectively]. Thus, GBA-positive Parkinson’s disease,
GBA-negative Parkinson’s disease and GBA-positive carriers
without Parkinson’s disease were all impaired in terms of propor-
tion of responses to the probed item (Fig. 4A). There was no
significant difference in  (model parameter measuring variability
around probed item orientation) between all four groups
demonstrating that change in the resolution of information in
VSTM does not contribute to the impairments observed.
Importantly, there was only a main effect of GBA-positive status
on b, the proportion of responses to non-probed items
[F(1,59) = 8.6, P = 0.005], but no effect of Parkinson’s disease
on these responses [F(1,59) = 3, P50.05; Fig. 4B]. This is the
pattern observed previously on simply plotting the distribution of
Figure 3 Performance of all participants in experimental working memory task. (A) Precision of memory. Memory precision in all patients
groups was significantly worse compared to healthy controls, patients with GBA-positive Parkinson’s disease (PD) performed significantly
worse compared to all tested participants (**P50.025, *P5 0.05). (B) Distribution of responses around the probed orientation for
patient groups and healthy participants. GBA carrier Parkinson’s disease patients made significantly less responses around the probed
orientation, followed by individuals with GBA mutation and non-carrier patients with Parkinson’s disease compared to healthy controls.
(C) Distribution of responses around non-probed orientations. Individuals with GBA mutation, with or without Parkinson’s disease made
significantly more responses centred on non-probed orientations.
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responses around non-probed orientations (Fig. 3C). Hence
GBA-positive individuals, regardless of whether they had
Parkinson’s disease, made significantly more misbinding errors,
responding with the orientations of non-probed items compared
to healthy controls and patients with GBA-negative Parkinson’s
disease.
Conversely, there was only a main effect of Parkinson’s disease
on , the proportion of random responses [F(1,59) = 6, P5 0.05],
with no effect of GBA positivity on these responses
[F(1,59) = 0.07, P = not significant; Fig. 4C]. Thus although the
presence of both Parkinson’s disease and GBA mutation resulted
in impaired VSTM performance, the sources of error associated
with each was different.
Visual short-term memory deficits
cannot be explained by impairments in
control tasks
There was no significant difference between the three groups and
healthy participants in the pre-cueing and one-item VSTM tasks.
Thus any difference in performance between groups is unlikely to
be due to being able to attend to different items presented
sequentially or due to differences in how information decays
over time for single items (although this does not mean that
there is no influence of maintenance duration on memory
precision). Finally, there was no significant difference in perform-
ance between the groups on the sensorimotor control task. This is
particularly important in the context of testing patients with
Parkinson’s disease who might have difficulties with dexterity in
using the dial. Our findings show that this is not a confounding
factor in interpreting the data.
Discussion
This study sought to examine whether visual VSTM impairments
associated with GBA mutation and Parkinson’s disease were due
to the same or different underlying mechanisms. The results dem-
onstrate that there are different patterns of deficit contributing to
VSTM deficits in individuals with Parkinson’s disease and those
who carry a GBA mutation. The results of three control tasks
show that in all groups, impaired performance is unlikely to be
explained by gross difficulties in attending to different serial pos-
itions in a sequence, differences in temporal decay of information
or sensorimotor deficits.
Although all tested groups (GBA-positive Parkinson’s disease,
GBA-negative Parkinson’s disease and GBA-positive subjects with-
out Parkinson’s disease) were significantly less precise in VSTM
recall than healthy controls, those who were GBA-positive and
also had Parkinson’s disease were significantly worse than those
who had either of these alone. Thus patients with GBA-positive
Parkinson’s disease appear to suffer a double ‘hit’ in VSTM
performance. What then is the nature of the mechanisms under-
lying VSTM deficits in GBA-positive and cases with Parkinson’s
disease?
The paradigm used here allowed us to analyse the sources of
error associated with GBA positivity and Parkinson’s disease. Error
in recall can potentially arise from several different sources. First, it
can be due to variability in memory for a feature, i.e. how well the
feature is stored. Second, error can arise due to systematic
corruption of the memory for the target item by other items
maintained in VSTM: interference or misbinding errors. Finally,
participants might guess due to failure to encode the probed
item or alternatively to retrieve it, e.g. due to fluctuations in
attention.
Figure 4 Model estimates for different sources of error in experimental working memory task. (A) Concentration parameter did not
differ significantly between all patient groups and healthy controls. (B) Probability of non-probed responses was significantly higher in
individuals with GBA mutation, with or without Parkinson’s disease (PD) compared to healthy controls and non-carrier patients with
Parkinson’s disease. (C) Probability of random responses was significantly higher in patients with Parkinson’s disease—with or without
GBA mutation—compared to healthy controls and individuals with GBA mutation without Parkinson’s disease.
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Those with GBA mutation, regardless of whether they
had Parkinson’s disease, made significantly greater responses to
non-probed items, responding more frequently with other
orientations retained in memory. Thus their memory was more
prone to be corrupted by misbinding errors in VSTM: failures to
correctly bind features (colour and orientation) of encoded items
in memory (Figs 3C and 4B). In contrast, those with Parkinson’s
disease, regardless of their GBA-positive status, were more prone
to making random responses or guesses. Thus there was a double
dissociation in the pattern of errors.
Human post-mortem specimens and GBA-positive mouse
models provide some support for distinct memory impairments
in Parkinson’s disease and GBA mutation. In our study
GBA-positive individuals, regardless of whether they had
Parkinson’s disease, showed increased misbinding errors. Both
mouse models of GBA mutation (Sardi et al., 2011) and human
Gaucher’s disease patients with dementia and Parkinson’s disease
have pathological changes in hippocampal and medial temporal
regions (Wong et al., 2004), which seem to play a critical role
in binding of information in VSTM (Olson and Marshuetz, 2005;
Parra et al., 2009, 2010; Della Sala et al., 2012; Pertzov et al.,
2013). Interestingly, Della Sala and colleagues (2012) have also
recently demonstrated that whereas patients with Alzheimer’s
disease (with presumed medial temporal pathology) demonstrate
misbinding errors, cases with Parkinson’s disease do not. These
authors examined the binding problem by measuring measure
VSTM performance for individual features alone as well as for
binding of features.
Although, we did not examine recall precision for colour
independently, we found no significant difference either between
patients groups or compared to healthy controls in the concentra-
tion parameter model estimate (Fig. 4A). Thus the resolution of
memory for orientation—independent of binding information—
was not disrupted. Together these findings suggest that there
might be specific VSTM binding deficits that occur in individuals
with medial temporal pathology, including perhaps those with
GBA mutation. These types of error might therefore be a
marker for detecting medial temporal dysfunction in different
patient populations.
By contrast, corruption of memory in patients with Parkinson’s
disease—regardless of GBA status—was due to an increase in
random responses, analogous to greater noise in a neural network,
which might not necessarily be specific to any particular brain
region but perhaps associated with fluctuations in performance,
possibly related to cholinergic deficits in Parkinson’s disease
(Kehagia et al., 2010). Alternatively, increased random
responses can be due to decrease in signal-to-noise ratio due to
deficits in the dopaminergic system in patients with Parkinson’s
disease, leading responses to fall within the random range
(Sawaguchi and Goldman-Rakic, 1991; Winterer and
Weinberger, 2004; Kroener et al., 2009). Individuals who were
GBA-positive and had Parkinson’s disease suffered from both
types of error (increased misbinding and random responses)
and as a consequence had far less precision in VSTM recall
than those who were GBA-positive or had Parkinson’s disease
alone.
Note that in our study, patients with Parkinson’s disease,
regardless of GBA status, were all ON dopaminergic medication.
Previously, we reported that VSTM precision, measured using
similar techniques, improves in patients with Parkinson’s disease
ON medication compared to OFF (Zokaei et al., 2012). Thus the
impairments observed here in both Parkinson’s disease groups
(GBA-positive and GBA-negative) cannot be attributed to
dopaminergic medication, although this clearly can modulate
performance, but in a beneficial way. One limitation of our
study is that relatively small numbers meant that we might have
missed differences in performance between cases with Gaucher’s
disease and GBA carriers who did not have Parkinson’s disease (in
our study the data from these groups was collapsed). Further
investigation will be required to investigate this particular issue
more definitively.
In summary, these findings demonstrate that GBA-positive
individuals without Parkinson’s disease have deficits in VSTM,
comparable to GBA-negative patients with Parkinson’s disease.
However, the sources of error underlying impairments in
Parkinson’s disease and GBA are dissociable. GBA-positive
individuals who develop Parkinson’s disease suffer a ‘double’ hit
and hence display worse performance overall. The results suggest
that measurement of VSTM provides a potentially useful tool to
probe cognitive deficits associated with GBA mutation and
Parkinson’s disease. GBA mutation is an important risk factor for
developing Parkinson’s disease but clearly most individuals who
have this do not develop Parkinson’s disease. Future research
might aim to examine whether it is possible to use the pattern
of VSTM errors associated with Parkinson’s disease (increased
random responses) to identify, at an early stage, individuals with
GBA mutations or other risk factors who are beginning to develop
Parkinson’s disease.
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